Skip to main content
Her Health Peptides

Medical disclaimer: This site is educational and does not provide individualized medical advice. Always consult a licensed clinician about your situation.

Share

GnRH antagonist

Degarelix

Brand names: Firmagon

Last reviewed 2026-08-01
No reliable evidence foundPregnancy/lactation data limited

Degarelix is approved mainly for prostate cancer. Women's health applications and evidence are limited; refer to current labels.

Key takeaways

  • Approved primarily in prostate cancer; women's health applications are limited or off-label.
  • Pregnancy and reproductive-potential counseling must follow label.

Mechanism and pathway

Competitively blocks GnRH receptors to rapidly suppress sex steroid production.

Peptide relationship: Degarelix is a synthetic GnRH antagonist peptide.

Route and formulation: Subcutaneous injection

Author

Ian Gauntt

RN, BSN — 10 years as a critical care nurse

Medical reviewer

Medical Reviewer (Pending Assignment)

Medical review pending assignment by a licensed clinician.

Last reviewed 2026-08-01Next review 2026-11-01

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.

Questions for Your ClinicianCompare medicines

The Women's Evidence Brief — one audit, one update, one evidence lesson each week.

Join the list